Literature DB >> 26354951

The Reliability of Estimating Ki Values for Direct, Reversible Inhibition of Cytochrome P450 Enzymes from Corresponding IC50 Values: A Retrospective Analysis of 343 Experiments.

Lois J Haupt1, Faraz Kazmi1, Brian W Ogilvie1, David B Buckley1, Brian D Smith1, Sarah Leatherman1, Brandy Paris1, Oliver Parkinson1, Andrew Parkinson2.   

Abstract

In the present study, we conducted a retrospective analysis of 343 in vitro experiments to ascertain whether observed (experimentally determined) values of Ki for reversible cytochrome P450 (P450) inhibition could be reliably predicted by dividing the corresponding IC₅₀ values by two, based on the relationship (for competitive inhibition) in which Ki = IC₅₀/2 when [S] (substrate concentration) = Km (Michaelis-Menten constant). Values of Ki and IC₅₀ were determined under the following conditions: 1) the concentration of P450 marker substrate, [S], was equal to Km (for IC₅₀ determinations) and spanned Km (for Ki determinations); 2) the substrate incubation time was short (5 minutes) to minimize metabolism-dependent inhibition and inhibitor depletion; and 3) the concentration of human liver microsomes was low (0.1 mg/ml or less) to maximize the unbound fraction of inhibitor. Under these conditions, predicted Ki values, based on IC₅₀/2, correlated strongly with experimentally observed Ki determinations [r = 0.940; average fold error (AFE) = 1.10]. Of the 343 predicted Ki values, 316 (92%) were within a factor of 2 of the experimentally determined Ki values, and only one value fell outside a 3-fold range. In the case of noncompetitive inhibitors, Ki values predicted from IC₅₀/2 values were overestimated by a factor of nearly 2 (AFE = 1.85; n = 13), which is to be expected because, for noncompetitive inhibition, Ki = IC₅₀ (not IC₅₀/2). The results suggest that, under appropriate experimental conditions with the substrate concentration equal to Km, values of Ki for direct, reversible inhibition can be reliably estimated from values of IC₅₀/2.
Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26354951     DOI: 10.1124/dmd.115.066597

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  9 in total

1.  Assessment of the CYP1A2 Inhibition-Mediated Drug Interaction Potential for Pinocembrin Using In Silico, In Vitro, and In Vivo Approaches.

Authors:  Shipra Bhatt; Sumit Dhiman; Vinay Kumar; Abhishek Gour; Diksha Manhas; Kuhu Sharma; Probir Kumar Ojha; Utpal Nandi
Journal:  ACS Omega       Date:  2022-06-02

2.  Effect of Myricetin on CYP2C8 Inhibition to Assess the Likelihood of Drug Interaction Using In Silico, In Vitro, and In Vivo Approaches.

Authors:  Shipra Bhatt; Diksha Manhas; Vinay Kumar; Abhishek Gour; Kuhu Sharma; Ashish Dogra; Probir Kumar Ojha; Utpal Nandi
Journal:  ACS Omega       Date:  2022-04-04

Review 3.  In vitro evaluation suggests fenfluramine and norfenfluramine are unlikely to act as perpetrators of drug interactions.

Authors:  Parthena Martin; Maciej Czerwiński; Pallavi B Limaye; Brian W Ogilvie; Steven Smith; Brooks Boyd
Journal:  Pharmacol Res Perspect       Date:  2022-06

4.  Kinetic Modeling of Time-Dependent Enzyme Inhibition by Pre-Steady-State Analysis of Progress Curves: The Case Study of the Anti-Alzheimer's Drug Galantamine.

Authors:  Doriano Lamba; Alessandro Pesaresi
Journal:  Int J Mol Sci       Date:  2022-05-03       Impact factor: 6.208

5.  Suillin: A mixed-type acetylcholinesterase inhibitor from Suillus luteus which is used by Saraguros indigenous, southern Ecuador.

Authors:  José Miguel Andrade; Pamela Pachar; Luisa Trujillo; Luis Cartuche
Journal:  PLoS One       Date:  2022-05-16       Impact factor: 3.752

6.  How Science Is Driving Regulatory Guidances.

Authors:  Xinning Yang; Jianghong Fan; Lei Zhang
Journal:  Methods Mol Biol       Date:  2021

7.  Physiologically based pharmacokinetic model predictions of natural product-drug interactions between goldenseal, berberine, imatinib and bosutinib.

Authors:  Jeffry Adiwidjaja; Alan V Boddy; Andrew J McLachlan
Journal:  Eur J Clin Pharmacol       Date:  2022-01-20       Impact factor: 2.953

8.  In Vitro and In Vivo Investigation of Potential for Complex CYP3A Interaction for PF-00251802 (Dagrocorat), a Novel Dissociated Agonist of the Glucocorticoid Receptor.

Authors:  Sharon L Ripp; Arnab Mukherjee; Heather Eng; Thomas Stock; Dona Fleishaker; Tina Checchio; Brinda Tammara
Journal:  Clin Pharmacol Drug Dev       Date:  2017-11-07

9.  Investigating the Contribution of Drug-Metabolizing Enzymes in Drug-Drug Interactions of Dapivirine and Miconazole.

Authors:  Guru Raghavendra Valicherla; Phillip Graebing; Junmei Zhang; Ruohui Zheng; Jeremy Nuttall; Peter Silvera; Lisa Cencia Rohan
Journal:  Pharmaceutics       Date:  2021-12-18       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.